☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Myeloid Leukemia
Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia
August 1, 2019
Takeda Enters into an Option Agreement with Ascentage Pharma for Olverembatinib to Treat Chronic Myeloid Leukemia
June 17, 2024
HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China
May 14, 2024
Remix Therapeutics Reports First Patient Dosing in Two of REM-422’s P-I Studies for Treating ACC and AML or High-Risk MDS
May 3, 2024
Enliven Therapeutics Reports the PoC Data from the P-I Study of ELVN-001 as a Treatment of Chronic Myeloid Leukemia
April 12, 2024
PureTech’s LYT-200 Gains the US FDA’s Fast Track Designation for Treating Head and Neck Cancers
April 11, 2024
SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)
March 27, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.